,GENE,MUTATION_REMARK,GENOMIC_MUTATION_ID,FUSION_ID,MUTATION_AA_SYNTAX,DISEASE,ACTIONABILITY_RANK,DEVELOPMENT_STATUS,DRUG_COMBINATION,TESTING_REQUIRED,TRIAL_STATUS,TRIAL_ID,TRIAL_NAME,COMPLETION_STATUS,TRIAL_PRIMARY_COMPLETION_DATE,PATIENT_PRESCREENING,RESULTS_AVAILABILITY,PROGRESSION_REMARK,SOURCE_TYPE,SOURCE,TREATMENT_HISTORY,PATIENT_AGE,PRIMARY_OUTCOME_MEASURE,NUMBER_OF_PATIENTS,TREATED_NUMBER,CONTROL_NUMBER,CONTROL_TREATMENT,ORR_TREAT,ORR_CON,ORR_CI,ORR_PVAL,DOR_TREAT,DOR_CON,DOR_CI,DOR_PVAL,PFS_TREAT,PFS_CON,PFS_HR,PFS_CI,PFS_PVAL,TTP_TREAT,TTP_CON,TTP_HR,TTP_CI,TTP_PVAL,DCR_TREAT,DCR_CON,DCR_PVAL,OS_TREAT,OS_CON,OS_HR,OS_CI,OS_PVAL,OBJ_RR_TREAT,CR_COUNT,PR_COUNT,SD_COUNT,RFS_TREAT,RFS_CON,RFS_HR,RFS_CI,RFS_PVAL,BLOOD_RESPONSE,RESPONSE_VALUE,TIMEPOINT,CLASSIFICATION_ID,LAST_UPDATED,COSMIC_PHENOTYPE_ID,SITE_PRIMARY_COSMIC,SITE_SUBTYPE1_COSMIC,SITE_SUBTYPE2_COSMIC,SITE_SUBTYPE3_COSMIC,HISTOLOGY_COSMIC,HIST_SUBTYPE1_COSMIC,HIST_SUBTYPE2_COSMIC,HIST_SUBTYPE3_COSMIC
0,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
1,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
2,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
3,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
4,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
5,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
6,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
7,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
8,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
9,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
10,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
11,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
12,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
13,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
14,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
15,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
16,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
17,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
18,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
19,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
20,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
21,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
22,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
23,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
24,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
25,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
26,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
27,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
28,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
29,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
30,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
31,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
32,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
33,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
34,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
35,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
36,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
37,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
38,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
39,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
40,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
41,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
42,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
43,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
44,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
45,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
46,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
47,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
48,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
49,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
50,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
51,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
52,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
53,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
54,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
55,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
56,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
57,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
58,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
59,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
60,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
61,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
62,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
63,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
64,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
65,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
66,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
67,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
68,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
69,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
70,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
71,APC,APC_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Binimetinib + Encorafenib,,Recruiting,NCT03839342,BEAVER,ECD,2023Dec01,Yes,Yes,,2,10.1200/JCO.2021.39.15_suppl.e15038,,,Overall Response Rate,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
72,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
73,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
74,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
75,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
76,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
77,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
78,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
79,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
80,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
81,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
82,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
83,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
84,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
85,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
86,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
87,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
88,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
89,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
90,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
91,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
92,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
93,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
94,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
95,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
96,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
97,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
98,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
99,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
100,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
101,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
102,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
103,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
104,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
105,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
106,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
107,BRAF,BRAF_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
108,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
109,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
110,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
111,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
112,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
113,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
114,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
115,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
116,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
117,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
118,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
119,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
120,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
121,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
122,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
123,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
124,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
125,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
126,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
127,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
128,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
129,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
130,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
131,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
132,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
133,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
134,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
135,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
136,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
137,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
138,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
139,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
140,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
141,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
142,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
143,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Radiotherapy + Trametinib,,"Active, not recruiting",NCT01740648,,PCD,2021Sep29,No,Yes,pCR 25%,1,32253228,,,Maximum tolerated dose/toxicity,9.0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,88.9,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
144,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
145,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
146,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
147,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
148,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
149,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
150,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
151,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
152,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
153,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
154,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
155,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
156,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
157,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
158,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
159,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
160,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
161,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
162,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
163,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
164,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
165,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
166,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
167,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
168,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
169,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
170,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
171,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
172,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
173,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
174,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
175,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
176,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
177,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
178,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
179,BRAF,BRAF_unspecified or KRAS_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
180,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
181,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
182,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
183,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
184,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
185,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
186,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
187,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
188,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
189,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
190,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
191,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
192,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
193,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
194,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
195,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
196,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
197,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
198,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
199,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
200,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
201,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
202,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
203,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
204,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
205,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
206,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
207,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
208,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
209,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
210,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
211,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
212,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
213,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
214,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
215,CD274,CD274_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy + Tiragolumab,,Recruiting,NCT05009069,,ECD,2023Jun30,No,No,,4,NCT05009069,,,"Complete response, Pathological complete response",76.0,,,Atezolizumab + Capecitabine or fluorouracil + Radiotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Jun27,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
216,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
217,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
218,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
219,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
220,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
221,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
222,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
223,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
224,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
225,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
226,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
227,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
228,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
229,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
230,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
231,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
232,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
233,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
234,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
235,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
236,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
237,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
238,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
239,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
240,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
241,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
242,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
243,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
244,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
245,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
246,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
247,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
248,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
249,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
250,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
251,ERBB2,ERBB2_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Capecitabine + Trastuzumab + Tucatinib,,Recruiting,NCT05672524,,ECD,2025Dec30,Overexpression,No,,4,NCT05672524,,,"Complete response, Pathological complete response",37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2023Jan12,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
252,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
253,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
254,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
255,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
256,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
257,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
258,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
259,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
260,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
261,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
262,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
263,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
264,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
265,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
266,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
267,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
268,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
269,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
270,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
271,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
272,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
273,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
274,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
275,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
276,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
277,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
278,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
279,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
280,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
281,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
282,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
283,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
284,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
285,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
286,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
287,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.54 v 1.54,4,NCT01507103,,,Immune cell infiltration,63.0,33.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
288,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
289,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
290,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
291,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
292,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
293,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
294,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
295,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
296,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
297,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
298,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
299,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
300,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
301,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
302,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
303,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
304,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
305,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
306,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
307,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
308,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
309,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
310,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
311,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
312,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
313,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
314,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
315,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
316,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
317,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
318,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
319,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
320,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
321,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
322,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
323,MLH1,MLH1_unspecified or MSH2_unspecified or MSH6_unspecified or PMS2_unspecified ,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 2,Chemotherapy + Cyclophosphamide + Emepepimut-S + Radiotherapy,,Completed,NCT01507103,SPRINT,PCD,2014Jun01,Expression confirmed,Yes,ICI 0.61 v 1.54,4,NCT01507103,,,Immune cell infiltration,57.0,27.0,30.0,Chemotherapy,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
324,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
325,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
326,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
327,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
328,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
329,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
330,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
331,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
332,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
333,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
334,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
335,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
336,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
337,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
338,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
339,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
340,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
341,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
342,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
343,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
344,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
345,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
346,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
347,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
348,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
349,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
350,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
351,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
352,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
353,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
354,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
355,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
356,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
357,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
358,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
359,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
360,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
361,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
362,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
363,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
364,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
365,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
366,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
367,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
368,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
369,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
370,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
371,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
372,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
373,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
374,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
375,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
376,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
377,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
378,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
379,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
380,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
381,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
382,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
383,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
384,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
385,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
386,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
387,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
388,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
389,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
390,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
391,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
392,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
393,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
394,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
395,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib + Infigratinib,,Completed,NCT01928459,,PCD,2016Aug01,Yes,Yes,,2,10.1200/JCO.2016.34.15_suppl.2500,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
396,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
397,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
398,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
399,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
400,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
401,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
402,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
403,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
404,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
405,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
406,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
407,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
408,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
409,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
410,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
411,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
412,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
413,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
414,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
415,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
416,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
417,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
418,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
419,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
420,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
421,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
422,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
423,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
424,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
425,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
426,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
427,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
428,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
429,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
430,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
431,PIK3CA,PIK3CA_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Alpelisib,,Completed,NCT01219699,,PCD,2015Feb05,Yes,Yes,,1,29401002,,,Maximum tolerated dose/toxicity,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.0,,,,,,,,,,COSO28664826,2022Nov28,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
432,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
433,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
434,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
435,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
436,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
437,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
438,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
439,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
440,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
441,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
442,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
443,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
444,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
445,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
446,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
447,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
448,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
449,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
450,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
451,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
452,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
453,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
454,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
455,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
456,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
457,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
458,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
459,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
460,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
461,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
462,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
463,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
464,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
465,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
466,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
467,PTEN,PTEN_unspecified,,,,large intestine / carcinoma / adenocarcinoma,3,Phase 1,Fluorouracil + Midostaurin + Radiotherapy,,Completed,NCT01282502,,PCD,2015Mar01,No,Yes,,2,10.1200/JCO.2018.36.15_suppl.e15674,,,Maximum tolerated dose/toxicity,19.0,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.0,,,,,,,,,,COSO28664826,2021May18,COSO28664826,large_intestine,rectum,NS,NS,carcinoma,adenocarcinoma,NS,NS
